Investing in tomorrow’s healthcare breakthroughs
SV HEALTH INVESTORS FORUM
SV Health Investors Signature System
SV Health Investors Signature System
rs Signature System
Signature name: SV3
Signature name: SV3
2 color : Symbol in PMS 376 Type in PMS 7701
color : Symbol in PMS 376 ype in PMS 7701
SV3 PMS 376 formats:
File names and formats: SV3.eps
File names and formats: SV3.eps SV3.jpg SV3.png
SV3.jpg SV3.png
Agenda
1:30 – 2:00pm UK Registration & refreshments
2:00 – 2:05pm UK Opening remarks
Kate Bingham, Managing Partner, SV Health Investors
2:05 – 2:35pm UK How close are we to preventing Alzheimer’s disease?
Maria Carrillo, Chief Science Officer and Medical Affairs Lead, Alzheimer’s Association
Richard Hargreaves, Senior Vice President Head of Neuroscience, Immunology, Integrative Sciences and Cardiovascular Research, Bristol Myers Squibb
Niranjan Bose, Managing Director, Health & Life Sciences, Gates Ventures
9:55 – 10:25am ET Chair: Jane Rhodes, CEO, AstronauTx
2:35 – 2:55pm UK Fireside chat – AI’s ultimate role in drug development
Charlotte Allerton, Senior Vice President, Head of Preclinical and Translational Sciences and Site Head, Cambridge US, Pfizer
9:55 – 10:25am ET Chair: Nikola Trbovic, Managing Partner, SV Health Investors
2:55 – 3:25pm UK Draig Therapeutics: Evolution of a new company
6:35 – 6:55am PT
Simon Ward, Co-Founder and Chief Scientific & Development Officer, Draig Therapeutics and Professor of Translational Drug Discovery, Cardiff University
Ivana Magovčević-Liebisch, Chief Executive Officer, Draig Therapeutics
Inder Kaul, Chief Medical Officer, Draig Therapeutics
9:35 – 9:55am ET Chair: Ruth McKernan, Operating Partner, SV Health Investors
3:25 – 3:55pm UK Role of collaborations between pharma and biotechs
Nisha Nanda, Group Vice President, Business Development, Head of Catalyze360, Eli Lilly & Co
Adrienne Brown, Head of Corporate Business Development, Eli Lilly & Co
Chair: Jamil Beg, Partner, SV Health Investors
4:00 – 4:25pm UK Networking Break
4:30 – 5:00pm UK US policy impact on new medicine development and utilisation
11:30 – 12:00pm ET
Peter Marks, former Director of the FDA Center for Biologics Evaluation and Research, Senior Vice President for Molecule Development and Head of Infectious Disease, Eli Lilly & Co
Murray Aitken, Senior Vice President, IQVIA and Executive Director, IQVIA Institute for Human Data Science
Chair: Jonathan Behr, Partner, SV Health Investors
5:00 – 5:30pm UK Evolving modalities in oncology
Uğur Şahin, Co-founder and CEO, BioNTech
Shelley Force Aldred, Co-founder and CEO, Rondo Therapeutics
Simon Puttick, Chief Scientific Officer, AdvanCell
12:00 – 12:30pm ET
Chair: Kevin Pojasek, President and CEO, Enara Bio
5:30 – 6:00pm UK What is next for Huntington’s disease?
Jan Thirkettle, CEO, Harness Therapeutics
David Reynolds, CEO, LoQus23 Therapeutics
Celine Bouquet, Head of Neuroscience and Ophthalmology Business Development, Roche
12:30 – 13:00pm ET Chair: Georgia Frost, Senior Associate, SV Health Investors
6:00 – 6:20pm UK Fireside chat – Building the modern oncology powerhouse
Susan Galbraith, Executive Vice President of Oncology R&D, AstraZeneca
1:00 – 1:20pm ET Chair: Ali Jazayeri, Operating Partner, SV Health Investors
6:25pm UK Closing remarks
Laurence Barker, Partner, SV Health Investors
6:30pm UK SV Celebration of Innovation